Skip to main content
Free research Free research Free target review with research home and workspace preview
Quick search ChEMBL 36
Loading Target Snapshot...
Querying ChEMBL database. This may take a few seconds.
Target Snapshot

CHEMBL5652 Target Snapshot

Glucose-dependent insulinotropic receptor · SINGLE PROTEIN · Homo sapiens

Back to Search Search this target Browse approvals Evidence Card
2,324Compounds
181Assays
5Approved Drugs
1,981.0Activities
Free Research Context

Research home keeps recent targets

This target will appear in recent viewed items on this browser. Use the demo workspace to preview watch rules and decision queues.

Research home Demo workspace
Navigation

Switch target

Move to another high-traffic target or paste a specific ChEMBL target ID.

Broader Open DB context

Frame the target before identity details

Structured disease, protein, and project context should read before the lower-level identity rail.

As of 2026-09-14

Glucose-dependent insulinotropic receptor shows clinical signal disease relevance led by diabetes mellitus. 3 more disease programs remain visible in the same review block. 1 linked drug keeps the current disease frame grounded. Protein identity stays anchored to UniProt Q8TDV5. Start with diabetes mellitus, then reuse UniProt Q8TDV5 as the stable protein anchor across project notes and exports.

Review focus
Review-ready target frame

Start with diabetes mellitus, then reuse UniProt Q8TDV5 as the stable protein anchor across project notes and exports.

ChEMBL component mapping + Open Targets-ready proxy + ChEMBL 36 via Core Engine 2026-09-14 1 linked drug
Open source guide
Disease program
diabetes mellitus

Glucose-dependent insulinotropic receptor shows clinical signal disease relevance led by diabetes mellitus. 3 more disease programs remain visible in the same review block. 1 linked drug remains visible in the same block.

Start review with diabetes mellitus because it currently carries clinical signal support. Linked drugs include MBX-2982. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.

Disease source · ChEMBL drug mechanism + indication proxy
Clinical signal Open Targets-ready proxy 1 linked drug
Open disease block
Identity Layer

Cross-source identity

Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.

This review treats Glucose-dependent insulinotropic receptor as ChEMBL target CHEMBL5652, mapped to UniProt Q8TDV5. Disease framing currently uses the Open Targets-ready proxy contract.

Review anchor
Glucose-dependent insulinotropic receptor
SINGLE PROTEIN · Homo sapiens
As of 2026-09-14
ChEMBL target ID
CHEMBL5652
Primary anchor for compounds, assays, approvals, and exports
ChEMBL 36 via Core Engine As of 2026-09-14
www.ebi.ac.uk
UniProt accession
Q8TDV5
Glucose-dependent insulinotropic receptor
UniProt accession via ChEMBL component mapping As of 2026-09-14
www.uniprot.org
Disease evidence contract
Open Targets-ready proxy
ChEMBL drug mechanism + indication proxy
ChEMBL drug mechanism + indication proxy As of 2026-09-14
www.ebi.ac.uk

Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.

Source Guidance

Start with the right source

Choose the first block or source based on the question you are trying to answer.

Need stable target naming and protein identity?
UniProt Target Context
UniProt accession via ChEMBL component mapping

Start here when your first question is whether Glucose-dependent insulinotropic receptor is the right protein anchor across sources, using UniProt Q8TDV5 as the stable mapping.

Jump to Protein Context
Need disease fit before discussing compounds?
Disease Relevance & Evidence Level
ChEMBL drug mechanism + indication proxy

Use this block first when you need to confirm why diabetes mellitus is currently framed as clinical signal support. It currently carries 1 linked drug in the same disease frame.

Jump to Disease Context
Need a meeting-ready explanation of why this target matters?
Evidence Card
Review-ready rationale with source-aware context

Open the one-page evidence card when you want the rationale, activity base, and attribution together.

Open Review-ready Card
Overview

Basic Information

Verify identity, organism, and the fastest next research jumps from the same page.

Preferred NameGlucose-dependent insulinotropic receptor
Target TypeSINGLE PROTEIN
OrganismHomo sapiens
UniProtQ8TDV5
ChEMBL ↗ UniProt ↗ NCBI Protein ↗

Next Actions

SearchRun a focused querySearch the database using this target name as the starting context. ApprovalsCheck approved moleculesSee which approved drugs connect back to this target and its surrounding signal space. FeedScan papers & updatesStay in the project thread while checking recent papers and platform updates.
UniProt Context

UniProt Target Context

Reviewable protein naming and mapping context for this target snapshot.

Protein LabelGlucose-dependent insulinotropic receptor
UniProt AccessionQ8TDV5
Component TypeProtein
Sequence Length335 aa

Glucose-dependent insulinotropic receptor

Source · UniProt accession via ChEMBL component mapping
UniProt Context ↗
Review Cue

How to read this target

Review this target as Glucose-dependent insulinotropic receptor, mapped to UniProt Q8TDV5. Sequence length is 335 aa.

Mapped IDQ8TDV5
Review nameGlucose-dependent insulinotropic receptor
OrganismHomo sapiens
Disease Relevance

Disease Relevance & Evidence Level

Open Targets-ready disease context using the current target-indication evidence contract.

Clinical signal Open Targets-ready proxy

Glucose-dependent insulinotropic receptor shows clinical signal disease relevance led by diabetes mellitus. 3 more disease programs remain visible in the same review block.

Clinical signal Phase II
diabetes mellitus
1 linked drug · 1 direct · 1 efficacy
Linked drugMBX-2982
Clinical signal Phase II
Disorder of lipid metabolism
1 linked drug · 1 direct · 1 efficacy
Linked drugGSK-1292263
Clinical signal Phase II
type 1 diabetes mellitus
1 linked drug · 1 direct · 1 efficacy
Linked drugMBX-2982
Clinical signal Phase II
type 2 diabetes mellitus
1 linked drug · 1 direct · 1 efficacy
Linked drugGSK-1292263
Source · ChEMBL drug mechanism + indication proxy
ChEMBL target record ↗
Review Cue

How to read disease relevance

Start review with diabetes mellitus because it currently carries clinical signal support. Linked drugs include MBX-2982. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.

Lead diseasediabetes mellitus
Strongest levelClinical signal
Block modeOpen Targets-ready proxy
Clinical Profile

Clinical Phase Distribution

5
Approved
3
Phase II
2
Phase I
Assay Mix

Activity Type Distribution

IC5039.0
KI49.0
EC501,893.0
Lead Set

Top Inhibitors (by pChEMBL)

ChEMBL IDpChEMBLTypeValue (nM)Phase
CHEMBL1771104 9.7 EC50 0.2 Preclinical
CHEMBL4093284 9.7 EC50 0.2 Preclinical
CHEMBL4104464 9.7 EC50 0.2 Preclinical
CHEMBL1771098 9.52 EC50 0.3 Preclinical
CHEMBL4098051 9.4 EC50 0.4 Preclinical
CHEMBL1773283 9.3 EC50 0.5 Preclinical
CHEMBL3354778 9.3 EC50 0.5 Preclinical
CHEMBL1773292 9.22 EC50 0.6 Preclinical
CHEMBL3893596 9.22 EC50 0.6 Preclinical
CHEMBL461384 9.19 EC50 0.65 Preclinical
Distribution

pChEMBL Value Distribution

57
5.0
157
5.5
262
6.0
353
6.5
398
7.0
289
7.5
184
8.0
70
8.5
18
9.0
4
9.5
pChEMBL
Approved Drugs

Approved Drugs

LOPERAMIDE HYDROCHLORIDE
CHEMBL1707
Approved 1976
Properties Compare Identifier
Assay Landscape

Assay Landscape

181
Total Assays
1,579
Tested Compounds
2
Assay Types
Functional — 152 assays, 1,579 compounds
BAO Format Assays Compounds Avg pChEMBL
cell-based format 122 1,393 7.0
assay format 17 88 7.5
single protein format 13 98 7.4
Binding — 29 assays, 154 compounds
BAO Format Assays Compounds Avg pChEMBL
single protein format 15 52 7.2
cell-based format 13 100 7.4
assay format 1 2 6.5

Confidence Score Distribution

Source · ChEMBL 36 via Core Engine